Skip to content

KDIGO 2024: chronic kidney disease

International KDIGO Current

KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease

Kidney Disease: Improving Global Outcomes CKD Work Group. Kidney Int. 2024;105(4S):S117–S314
Summary checked against the source: 2026-11

Read or download the original

KDIGO grades: 1 = we recommend, 2 = we suggest; evidence A–D; PP = ungraded practice point. Pages are journal supplement pages (S…).

At a glance

  1. CKD = abnormal kidney structure or function for >3 months, with health implications. Classify by Cause, GFR (G1–G5) and Albuminuria (A1–A3): the CGA system. [S149]
  2. Test with both eGFR and urine ACR, and repeat abnormal results to confirm. [PP · S149]
  3. eGFRcr to start; eGFRcr-cys when creatinine is unreliable and the decision matters. [1B · S149; 1C · S151]
  4. The four pillars: RAS inhibitor, SGLT2 inhibitor, statin, and (in type 2 diabetes with albuminuria) finerenone, plus a GLP-1 RA if glucose isn't controlled. [S158–S160]
  5. BP target SBP <120 mm Hg if tolerated. [2B · S158]
  6. SGLT2i for CKD with eGFR ≥20 and ACR ≥200 mg/g, or with heart failure; and keep it going below 20. [1A · S159]
  7. Risk equations (e.g. KFRE) guide referral and KRT planning. [1A · S156]

Staging

GFR category eGFR (mL/min/1.73 m²) Description
G1 ≥90 Normal or high
G2 60–89 Mildly decreased
G3a 45–59 Mildly to moderately decreased
G3b 30–44 Moderately to severely decreased
G4 15–29 Severely decreased
G5 <15 Kidney failure
Albuminuria ACR mg/g (mg/mmol) Description
A1 <30 (<3) Normal to mildly increased
A2 30–300 (3–30) Moderately increased
A3 >300 (>30) Severely increased

Risk of death, cardiovascular events, kidney failure and AKI rises with both lower eGFR and higher ACR. In the 2024 heat maps, for example, the hazard of kidney failure replacement therapy at eGFR <30 with ACR ≥300 mg/g is several hundred times the reference. Adapted from KDIGO 2024 chapter 1 and Figure 1 [S136, S149]

Evaluation

  • Find the cause: history, examination, urinalysis, imaging, and genetic testing where appropriate. Kidney biopsy is acceptable and safe when it will change management. [2D · S150]
  • Use a validated GFR equation, not creatinine alone. [1D · S154]
  • Point-of-care creatinine and urine albumin are acceptable where laboratory access is limited. [2C · S155]
  • Kidney failure risk in G3–G5 with an externally validated equation such as KFRE. [1A · S156]
Kidney failure risk Use
5-year risk 3–5% Refer to nephrology
2-year risk >10% Multidisciplinary care
2-year risk >40% KRT modality education, access planning, transplant referral

Adapted from KDIGO 2024 practice points 2.2.1–2.2.3 [S156]

Slowing progression

Recommended (grade 1)

  • RASi (ACEi or ARB) for CKD G1–G4 with A3, without diabetes. [1B · S158]
  • RASi for diabetes with A2 or A3. [1B · S158]
  • Never combine ACEi, ARB and a direct renin inhibitor. [1B · S158]
  • SGLT2i for type 2 diabetes with CKD and eGFR ≥20. [1A · S159]
  • SGLT2i for CKD with eGFR ≥20 and ACR ≥200 mg/g, or with heart failure, whatever the albuminuria. [1A · S159]
  • Long-acting GLP-1 RA in type 2 diabetes with CKD not at glycaemic target on metformin and SGLT2i. [1B · S160]
  • Moderate exercise ≥150 minutes a week. [1D · S157]

Suggested (grade 2)

  • SBP <120 mm Hg when tolerated, with standardised office measurement. [2B · S158]
  • RASi for A2 without diabetes. [2C · S158]
  • SGLT2i for eGFR 20–45 with ACR <200 mg/g. [2B · S159]
  • Finerenone (non-steroidal MRA) for type 2 diabetes with eGFR >25, normal potassium and ACR >30 mg/g despite maximum RASi. [2A · S159]
  • Protein 0.8 g/kg/day in G3–G5; sodium <2 g/day (<5 g salt). [2C · S157]

Practice points on SGLT2i [S159]

  • Continue below eGFR 20 unless not tolerated or dialysis starts.
  • Withhold during prolonged fasting, surgery or critical illness (ketosis risk).
  • The initial eGFR dip is expected and isn't a reason to stop.

Complications and cardiovascular risk

Issue Guidance Grade
Statins Age ≥50 with eGFR <60 (not on dialysis): statin or statin + ezetimibe 1A
Age ≥50, G1–G2: statin 1B
Age 18–49 with diabetes, CAD, previous stroke or high 10-year risk: statin 2A
Aspirin Low-dose for secondary prevention 1C
Stable IHD Initial conservative strategy is an acceptable alternative to invasive 2D
AF NOACs over warfarin in G1–G4, with dose adjustment 1C
Gout Symptomatic hyperuricaemia: urate-lowering treatment 1C
Don't treat asymptomatic hyperuricaemia to slow CKD 2D
Acidosis Consider treatment to prevent bicarbonate <18 mmol/L PP
Hyperkalaemia Individualised diet and drugs; limit processed foods rich in potassium PP

Adapted from KDIGO 2024 sections 3.10–3.16 [S160–S163]

Referral

flowchart LR
    D["Diagnosis of CKD"] --> C1["Causes:<br/>uncertain cause, hereditary disease,<br/>recurrent extensive stones"]
    D --> C2["eGFR or risk of KRT:<br/>5-year KRT risk &gt;3–5%,<br/>eGFR &lt;30, sustained fall &gt;20%<br/>(&gt;30% after starting RASi or SGLT2i)"]
    D --> C3["Albuminuria and haematuria:<br/>ACR ≥300 mg/g with haematuria,<br/>doubling of albuminuria, ACR &gt;700 mg/g,<br/>red cell casts or RBC &gt;20/hpf"]
    D --> C4["Others:<br/>hypertension on ≥4 drugs, persistent<br/>potassium problems, acidosis, anaemia,<br/>bone disease, malnutrition"]
    C1 --> A1["Further evaluation and<br/>specialist management"]
    C2 --> A2["Plan and prepare<br/>for KRT"]
    C3 --> A3["Further evaluation<br/>and management"]
    C4 --> A4["Manage CKD<br/>complications"]
Adapted from KDIGO 2024 Figure 48 [S166]

Clinical pearls

  • CKD needs 3 months. CGA classification: cause, G1–G5, A1–A3.
  • ACR 30 mg/g = 3 mg/mmol; 300 mg/g = 30 mg/mmol.
  • Pillars: RASi + SGLT2i + statin ± finerenone ± GLP-1 RA.
  • Creatinine rise up to 30% after starting a RASi is acceptable.
  • SBP <120 (KDIGO), versus <130/80 in most cardiology guidelines.

Classes and levels of evidence

How KDIGO CKD 2024 grades its recommendations. Adapted from KDIGO CKD 2024 grading system [S117–S314]. Hover over any class or level cited on this page to see what it means.

Grade Meaning Wording used
1A Level 1, strong: we recommend. Most people would want this course of action; quality A (high): we are confident that the true effect is close to the estimate
1B Level 1, strong: we recommend. Most people would want this course of action; quality B (moderate): the true effect is likely close to the estimate but may be substantially different
1C Level 1, strong: we recommend. Most people would want this course of action; quality C (low): the true effect may be substantially different
1D Level 1, strong: we recommend. Most people would want this course of action; quality D (very low): the estimate is very uncertain and often far from the truth
2A Level 2, weak: we suggest. Most people would want it, but many would not; quality A (high): we are confident that the true effect is close to the estimate
2B Level 2, weak: we suggest. Most people would want it, but many would not; quality B (moderate): the true effect is likely close to the estimate but may be substantially different
2C Level 2, weak: we suggest. Most people would want it, but many would not; quality C (low): the true effect may be substantially different
2D Level 2, weak: we suggest. Most people would want it, but many would not; quality D (very low): the estimate is very uncertain and often far from the truth
Practice point Ungraded expert advice where a systematic review was not done
Not graded Ungraded statement based on common sense, or on a topic with no basis for grading evidence

KDIGO grades each recommendation by strength (1 = "we recommend", 2 = "we suggest") and quality of evidence (A high, B moderate, C low, D very low), written together as 1B, 2C and so on. Practice points (PP) are ungraded expert advice where no systematic review was done. Older KDIGO guidelines also have "Not Graded" statements.